Brolucizumab Comparable to Aflibercept for DME
Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.
Telehealth Could Be Feasible Alternative in Ophthalmology
Patients who utilized virtual and in-person visits had comparable numbers of follow-ups, referrals, and outpatient surgeries.
Fluticasone Acetate Implant May Improve Retinal Vein Occlusion Macular Edema
The implant was linked to visual acuity improvements at final follow-up visit.
Yearly Dosing of AXT107 May Have Promise for Retinal Diseases
Animal models suggest the investigative treatment is safe and tolerable in treating retinal vascular diseases.
Researchers Compare Intravitreal Implants for Non-Infectious Posterior Uveitis
There were no significant differences between dexamethasone and fluocinolone acetonide intravitreal implants in controlling inflammation; however, the latter is considered more difficult to use.
Could Dapagliflozin Treat Diabetic Retinopathy?
A discussion with an investigator on how the SGLT-2 inhibitor may help affected patients.
Data Supports Fluocinolone Acetonide Micro Implant Efficacy for Chronic DME
Up to 77% of patients maintained or improved best-corrected visual acuity at 12 month post-injection.
Missed Ophthalmology Appointments More Likely in Minority Populations
Hispanic and Black patients with chronic eye diseases had higher odds of missing out on appointments.
Study Offers Insight into Post-Intravitreal Injection Urgent Visits
Investigators report a low incidence rate of unscheduled or urgent visits within 7 days of injection.
Anti-VEGF Reduces Risk of Proliferative Diabetic Retinopathy Progression
A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.
Addressing Frequent Cardiovascular Risk Factors in Visually Impaired Patients
CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?
What Influences Diabetic Macular Edema Resolution with Anti-VEGF?
An assessment of VISTA and VIVID patient data uncovered surprising risk factors associated with aflibercept success or failure in DME resolution.
Investigators Explore the Impact of COVID-19 Lockdowns on Ocular Therapies
Patients with nAMD, DME, and RVO received fewer intravitreal injections between pre- and post-lockdown periods.
Edmund Tsui, MD: Making the Most of the ARVO 2021 Agenda
The UCLA expert discusses the lengthy virtual agenda of this year's meeting, as well as his own session recommendations and key discussions.
Statins May Not Halt Progression from AMD to nAMD
These findings corroborate similar conclusions presented last year at ARVO.
Study Suggests Glaucoma-Induced Vision Loss is on the Rise
Age-adjusted glaucoma blindness has nonetheless seen a downward trend between 2000 and 2020.
ADVM-022 Gene Therapy for nAMD May Reduce Anti-VEGF Injection Burden
The single-injection investigative gene therapy may help with providing continuous expression of aflibercept.
Gene Therapy BIIB112 Promising for X-Linked Retinitis Pigmentosa
The AAV8 vector–based gene therapy was associated with improvements in 2 measures of visual function.
Home Monitoring May Reduce Neovascularization Risks in Patients with AMD
An FDA-approved device, provided to eligible patients with age-related macular degeneration, showed ability to detect CNV risks over 5 years.
Delaying Anti-VEGF Treatment for DME Likely to Worsen Visual Outcomes
The majority of patients with a treatment gap longer than 12 weeks had worsening visual acuity, notes a new ARVO study.
Dapagliflozin May Benefit Patients with Diabetic Retinopathy
The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.
Childhood Strabismus Increases Risk for Mental Health Disorders
More research is needed to fully understand the associations with different types of strabismus
Undetected Eye Disease Burden High in African American Populations
Patients with diabetes mellitus have the highest odds of being diagnosed with an undetected eye disease.
Faricimab and PDS Ranibizumab May Progress Anti-VEGF Treatment Duration
An expert discusses his interest in a pair of macular degeneration and diabetic macular edema treatments that may provide less burden and consistent efficacy in patients.
Cardiovascular Disease Risk Factors More Prevalent in Visually-Impaired Adults
A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.
Aflibercept Benefits Non-Proliferative Diabetic Retinopathy Visual Acuity at 2 Years
Allen Ho, MD, discusses the Protocol W outcomes and what they indicate for prescribing ophthalmologists.
Interim Data Shows Real-World Insights into Ranibizumab Treatment Practices
The PACIFIC study is currently evaluating health care management practice with intravitreal ranibizumab 0.5 mg for various ophthalmologic diseases.
Study Explores Associations Between DME and Proliferative Diabetic Retinopathy
An ARVO 2021 study characterizes patients with diabetic retinopathy who have also developed diabetic macular edema.
Study Identifies Potential Type 2 Diabetes plus Dry Eye Biomarkers
New research shows patients with both conditions have greater levels of particular cytokines and metabolic proteins.
Expanding Sepofarsen Understanding in LCA10
After promising early findings for the investigative therapy in a rare form of blindness, investigators turn to the next phase.